Renal Cell Carcinoma

  • Bin S. Teh
  • Hiromichi Ishiyama
  • Angel I. Blanco
  • Lee E. Ponsky
  • Simon S. Lo
  • Bo Xu
  • E. Brian Butler
  • Robert J. Amato
  • Rodney J. Ellis
Part of the Medical Radiology book series (MEDRAD)


Renal cell carcinoma (RCC) is traditionally considered to be a “radioresistant” malignancy. Surgery has been the mainstay of treatment in the management of primary RCC, from open to laparoscopic and more recently robotic radical nephrectomy. For selected patients, nephron-sparing partial nephrectomy is performed. Other local therapy options include radiofrequency ablation (RFA), cryoablation, and other ablative procedures. Adjuvant radiotherapy after nephrectomy in high-risk patients has been shown to improve local control but not overall survival. These patients have high propensity for developing distant metastases which may explain the lack of survival benefits with adjuvant radiotherapy. In addition, it is also very difficult to deliver high dose radiation with conventional technique because of the radiation tolerance of normal tissues, especially the small bowels. With the approved use of various effective targeted agents, patients with high risk and metastatic RCC are now surviving longer and the role of local therapy for both primary and metastatic RCC has also become more important. Stereotactic radiosurgery (SRS) has been shown to be very effective in the management of RCC brain metastases. Extracranially, conventional radiotherapy has played an important role in the palliation of metastatic RCC associated symptoms such as pain. Stereotactic body radiation therapy (SBRT), a continuum of technological advances in SRS from intracranial to extracranial application, has now evolved to show promise in the local management of primary RCC, local recurrence, and various metastatic sites.


Renal Cell Carcinoma Partial Nephrectomy Intensity Modulate Radiation Therapy Stereotactic Body Radiation Therapy Metastatic Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Beitler JJ, Makara D, Silverman P et al (2004) Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 27:646–648PubMedCrossRefGoogle Scholar
  2. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ (2008) Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int 102:358–363PubMedCrossRefGoogle Scholar
  3. Culine S, Bekradda M, Kramar A et al (1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83:2548–2553PubMedCrossRefGoogle Scholar
  4. Deschavanne PJ, Fertil B (1996) A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 34:251–266PubMedCrossRefGoogle Scholar
  5. DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn BW (1997) Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J Urol 158:746–749PubMedCrossRefGoogle Scholar
  6. Doh L, Curtis AE, Teh BS (2006) Renal-cell carcinoma. N Engl J Med 354:1095–1096PubMedCrossRefGoogle Scholar
  7. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659PubMedCrossRefGoogle Scholar
  8. Fokas E, Henzel M, Hamm K et al (2010) Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol 186:210–217PubMedCrossRefGoogle Scholar
  9. Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679–694PubMedCrossRefGoogle Scholar
  10. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159PubMedCrossRefGoogle Scholar
  11. Gerszten PC, Burton SA, Ozhasoglu C, Vogel WJ, Welch WC, Baar J, Friedland DM (2005) Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J Neurosurg 3:288–295Google Scholar
  12. Hoshi S, Jokura H, Nakamura H, Shintaku I, Ohyama C, Satoh M, Saito S, Fukuzaki A, Orikasa S, Yoshimoto T (2002) Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol 9:618–625PubMedCrossRefGoogle Scholar
  13. Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, Zhu JX, Gao Y, Mai W, Furge K, Qian CN et al (2009) Radiosensitization by inhibiting stat1 in renal cell carcinoma. Int J Radiat Oncol Biol Phys 73:288–295PubMedCrossRefGoogle Scholar
  14. Ishiyama H, Teh BS, Ren H, Chiang S, Tann A, Blanco AI et al. (2012) Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin GU Cancer (E-published ahead of print)Google Scholar
  15. Jhaveri P, Teh BS, Bloch C, Amato R, Butler EB, Paulino AC (2008) Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) 22:782–788Google Scholar
  16. Jhaveri P, Teh BS, Paulino AC, Blanco AI, Lo SS, Butler EB, Amato RJ (2012) A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy for renal cell carcinoma metastases. Acta Oncol 51:584–588PubMedCrossRefGoogle Scholar
  17. Juusela H, Malmio K, Alfthan O, Oravisto KJ (1977) Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 11:277–281PubMedCrossRefGoogle Scholar
  18. Kaplan ID, Redrosa I, Martin C et al (2010) Results of a phase I dose escalation study of stereotactic radiosurgery for primary renal tumors. Intl J Radiat Oncol Biol Phys 2010(78):S191Google Scholar
  19. Karam JA, Wood CG (2011) The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metatarsectomy. Hematol Oncol Clin North Am 25:753–764PubMedCrossRefGoogle Scholar
  20. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ (2007) Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin GU Cancer 5:291–294Google Scholar
  21. Kjaer M, Iversen P, Hvidt V, Bruun E, Skaarup P, Hansen JB, Frederiksen PL (1987) A randomized trial of postoperative radiotherapy versus observation in stage ii and iii renal adenocarcinoma. A study by the copenhagen renal cancer study group. Scand J Urol Nephrol 21:285–289PubMedCrossRefGoogle Scholar
  22. Kumar T, Patel N, Talwar A (2010) Spontaneous regression of thoracic malignancies. Respir Med 104:1543–1550PubMedCrossRefGoogle Scholar
  23. Lee J, Hodgson D, Chow E, Bezjak A, Catton P, Tsuji D et al (2005) A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 104:1894–1900PubMedCrossRefGoogle Scholar
  24. Lo SS, Cardenes HR, Teh BS, Fakiris AJ, Henderson MA, Papiez L et al (2008) Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev Anticancer Ther 8(12):1939–1951PubMedCrossRefGoogle Scholar
  25. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L et al (2010) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7:44–54PubMedCrossRefGoogle Scholar
  26. Maor MH, Frias AE, Oswald MJ (1988) Palliative radiotherapy for brain metastases in renal carcinoma. Cancer 62:1912–1917PubMedCrossRefGoogle Scholar
  27. Mickisch GHJ, Garin A, Poppel Hv, Prijck Ld, Sylvester R et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carincoma: a randomized trial. Lancet 358:966–970PubMedCrossRefGoogle Scholar
  28. Mortensen H (1948) Transthoracic nephrectomy. J Urol 60:855–858PubMedGoogle Scholar
  29. Nguyen QN, Shiu AS, Rhines LD et al (2010) Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76:1185–1192PubMedCrossRefGoogle Scholar
  30. Noel G, Valery CA, Boisserie G, Cornu P, Hasboun D, Marc Simon J, Tep B, Ledu D, Delattre JY, Marsault C, Baillet F, Mazeron JJ (2004) LINAC radiosurgery for brain metastasis of renal cell carcinoma. Urol Oncol 22:25–31PubMedCrossRefGoogle Scholar
  31. Ponsky LE, Mahadevan A, Gill IS et al (2007) Renal radiosurgery: initial clinical experience with histological evaluation. Surg Innov 14:265–269PubMedCrossRefGoogle Scholar
  32. Potters L, Steinberg M, Rose C et al (2004) American society for therapeutic radiology and oncology and american college of radiology practice guidelines for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 60:1026–1032PubMedCrossRefGoogle Scholar
  33. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342–349PubMedCrossRefGoogle Scholar
  34. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D (2011) Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control. Radiat Oncol 6:34PubMedCrossRefGoogle Scholar
  35. Suzuki K, Ushiyama T, Mugiya S, Kageyama S, Saisu K, Fujita K (1997) Hazards of laparoscopic adrenalectomy in patients with adrenal malignancy. J Urol 158:2227PubMedCrossRefGoogle Scholar
  36. Svedman C, Sandstrom P, Pisa P et al (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45:870–875PubMedCrossRefGoogle Scholar
  37. Svedman C, Karlsson K, Rutkowska E et al (2008) Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 47:1578–1583PubMedCrossRefGoogle Scholar
  38. Tan MH, Rogers CG, Cooper JT, Ditlev JA, Maatman TJ, Yang X, Furge KA, Teh BT (2004) Gene expression profiling of renal cell carcinoma. Clin Cancer Res 10:6315S-6321S Google Scholar
  39. Tanvetyanon T, Robinson LA, Schell MJ et al (2008) Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26:1142–1147PubMedCrossRefGoogle Scholar
  40. Teh BS, Bloch C, Paulino AC, Shen S, Hinckley L, Baskin D, Butler EB, Amato R (2007a) Pathologic complete response in renal cell carcinoma brain metastases treated with stereotactic radiosurgery. Clin Genitourin Cancer 5:334–337PubMedCrossRefGoogle Scholar
  41. Teh BS, Bloch C, Galli-Guevara M et al (2007b) The treatment and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 3(1):e6PubMedGoogle Scholar
  42. Teh BS, Paulino AC, Lu HH, Chiu JK, Richardson SL, Chiang S, Amato RJ, Butler EB, Bloch C (2007c) Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites. Technol Cancer Res Treat 6:347–354PubMedGoogle Scholar
  43. Teh BS, Ishiyama H, Mathews T, Xu B, Butler EB, Mayr NA, Lo SS, Lu JJ, Blanco AI, Paulino AC, Timmerman RD (2010) Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discov Med 10(52):255–262PubMedGoogle Scholar
  44. Thompson IM, Peek M (1988) Improvement in survival of patients with renal cell carcinoma-the role of the serendipitously detected tumor. J Urol 140:487–490PubMedGoogle Scholar
  45. Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, Martin E, Abdulrahman R, Swann S, Fowler J, Choy H (2006) Accreditation and quality assurance for radiation therapy oncology group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol 45:779–786PubMedCrossRefGoogle Scholar
  46. Torok J, Wegner RE, Burton SA, Heron DE (2011) Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol 7(1):145–151PubMedCrossRefGoogle Scholar
  47. Twomey P, Montgomery C, Clarck O (1982) Successful treatment of adrenal metastases from large-cell carcinoma of the lung. JAMA 248:581–583PubMedCrossRefGoogle Scholar
  48. Van der Werf-Messing B (1973) Proceedings: carcinoma of the kidney. Cancer 32:1056–1061PubMedCrossRefGoogle Scholar
  49. Walsh L, Stanfield JL, Cho LC et al (2006) Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol 50:795–800PubMedCrossRefGoogle Scholar
  50. Wersäll PJ, Blomgren H, Lax I et al (2005) Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 77:88–95PubMedCrossRefGoogle Scholar
  51. Wersäll PJ, Blomgren H, Pisa P, Lax I, Kälkner K-M, Svedman C (2006) Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 45:493–497PubMedCrossRefGoogle Scholar
  52. Wilson D, Hiller L, Gray L, Grainger M, Stirling A, James N (2003) The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 15:400–407CrossRefGoogle Scholar
  53. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29Google Scholar
  54. Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, Mechalakos J, Zatcky Fuks Z, Yamada Y (2012) Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82:1744–1748PubMedCrossRefGoogle Scholar
  55. Zeng ZC, Tang ZY, Fan J et al (2005) Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Jpn J Clin Oncol 35:61–67PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Bin S. Teh
    • 1
  • Hiromichi Ishiyama
    • 2
  • Angel I. Blanco
    • 1
  • Lee E. Ponsky
    • 3
  • Simon S. Lo
    • 4
  • Bo Xu
    • 1
  • E. Brian Butler
    • 1
  • Robert J. Amato
    • 5
  • Rodney J. Ellis
    • 4
  1. 1.Department of Radiation OncologyThe Methodist Hospital, Cancer Center and Research InstituteHoustonUSA
  2. 2.Department of Radiology and Radiation OncologyKitasato University School of MedicineSagamiharaJapan
  3. 3.Center for Urologic Oncology and Minimally Invasive Therapies, Urology InstituteUniversity Hospitals Case Medical Center, Case Western Reserve University School of MedicineClevelandUSA
  4. 4.Department of Radiation OncologyUniversity Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve UniversityClevelandUSA
  5. 5.Department of Internal Medicine, Division of OncologyUniversity of Texas Health Sciences CenterHoustonUSA

Personalised recommendations